Takeda Pharmaceutical Ltd ADR (TAK)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 03/31
| 12-2022 | 09-2022 | 06-2022 | 03-2022 | 12-2021 | |
| Sales | 7,785,512 | 7,216,610 | 7,487,980 | 7,503,526 | 7,931,387 |
| Cost of Goods | 2,385,408 | 2,199,204 | 2,255,191 | 2,669,319 | 2,476,355 |
| Gross Profit | 5,400,104 | 5,017,406 | 5,232,789 | 4,834,207 | 5,455,032 |
| Operating Expenses | 4,356,883 | 4,265,664 | 4,074,007 | 4,906,480 | 4,430,319 |
| Operating Income | 1,043,629 | 751,954 | 1,158,965 | -71,956 | 1,025,059 |
| Interest Expense | 566,218 | 387,382 | 427,111 | 64,019 | 411,013 |
| Other Income | 283,375 | 100,181 | 465,288 | -394,709 | 21,252 |
| Pre-tax Income | 760,786 | 464,753 | 1,197,142 | -530,684 | 635,298 |
| Income Tax | -85,172 | 20,282 | 388,480 | 172,031 | 126,482 |
| Net Income Continuous | 845,958 | 444,470 | 808,662 | -702,715 | 508,816 |
| Minority Interests | 156 | -72 | 54 | -170 | 449 |
| Net Income | $845,802 | $444,542 | $808,608 | $-702,545 | $508,367 |
| EPS Basic Total Ops | 0.27 | 0.14 | 0.26 | -0.22 | 0.16 |
| EPS Basic Continuous Ops | 0.27 | 0.14 | 0.26 | -0.22 | 0.16 |
| EPS Diluted Total Ops | 0.27 | 0.14 | 0.26 | -0.22 | 0.16 |
| EPS Diluted Continuous Ops | 0.27 | 0.14 | 0.26 | -0.23 | 0.16 |
| EBITDA(a) | $2,266,866 | $1,881,160 | $2,377,752 | $1,326,372 | $2,236,071 |